title: Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension.
abstract: BACKGROUND
  Patients with precapillary pulmonary hypertension (PH) exhibit a poor exercise capacity due to an impaired vasodilatory response of their pulmonary arteries. By causing the pulmonary artery to dilate, inhaled nitric oxide (NO) may allow an increase in exercise capacity in patients with PH.
  
  
  RESULTS
  On 2 separate days, 3 days apart, 14 patients with precapillary PH (10 primary PH, 4 residual PH after correction of an intracardiac shunt; age, 40+/-12 years; mean pulmonary artery pressure, 60+/-23 mm Hg) performed exercise, with and without inhalation of 20 ppm NO, on a cycle ergometer. The work rate was increased 15 W/min until their symptom-limited maximum, with breath-by-breath gas analysis. Patients were randomly and blindly selected to inhale NO on either their first or second test. Peak exercise load and anaerobic threshold tended to increase, but not significantly. Peak oxygen consumption (f1.gif" BORDER="0">O(2)) and Deltaf1.gif" BORDER="0">O(2)/DeltaW ratio increased significantly, by 18% and 22%, respectively (peak f1.gif" BORDER="0">O(2), 13.6+/-3.6 to 16.0+/-4. 1 mL. kg(-1). min(-1); Deltaf1.gif" BORDER="0">O(2)/DeltaW ratio, 5. 8+/-2.4 to 7.1+/-2.3 mL. kg(-1). min(-1). W(-1); both P<0.01). Peak f1.gif" BORDER="0">O(2) increased >10% in 12 of the 14 patients. However, respiratory quotient at peak exercise decreased from 1. 22+/-0.15 to 1.09+/-0.15 (P<0.01).
  
  
  CONCLUSIONS
  Inhaled NO substantially increases oxygen consumption at the same workload during exercise. This finding supports the possibility of ambulatory NO inhalation therapy in patients with precapillary PH.
authors.affiliation: Division of Cardiology and Pulmonary Circulation, Department of Medicine, National Cardiovascular Center, and Division of Circulatory Dynamics, National Cardiovascular Research Institute, Suita, Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Hasuda
authors.forename: T
authors.initials: T
authors.lastname: Satoh
authors.forename: A
authors.initials: A
authors.lastname: Shimouchi
authors.forename: F
authors.initials: F
authors.lastname: Sakamaki
authors.forename: S
authors.initials: S
authors.lastname: Kyotani
authors.forename: T
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Y
authors.initials: Y
authors.lastname: Goto
authors.forename: N
authors.initials: N
authors.lastname: Nakanishi
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D017079:Exercise Tolerance / Q000187:drug effects*; D005260:Female; D006439:Hemodynamics; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000494:pharmacology / Q000627:therapeutic use*; D010101:Oxygen Consumption
chemical_list: D009569:Nitric Oxide